الفهرس 
OVERVIEW ON LYMPHOID NEOPLASMSOnly 14 pages are availabe for public view
 |  | from | 283 |  |  |
| | | from | 283 | | |
Abstract
Background and study aims: Mature B-cell neoplasms represent a wide spectrum of malignant disease characterized by accumulation of mature B lymphocytes in the lymphoid tissues, bone marrow and peripheral blood. Flow cytometric immunophenotyping is an indispensable tool in the detection of lymphoid and plasma cell neoplasia.This study aimed to evaluate whether the inclusion of CD43, CD200, CD1d and CD160 in a conventional immunophenotypic panel could be useful to improve the diagnostic accuracy of B-cell lymphomas by flowcytometric analysis or not.
Patients and methods: This study was conducted on 62 adult patients newly diagnosed as having CD5+ mature B-cell neoplasms. They were recruited from the Haematology/Oncology unit of Ain Shams University hospitals. The 62 patients were classified into: 31 CLL cases, 5 aCLL cases, 9 B-PLL cases, 10 MCL cases, 5 SMZl cases and 2 DLBCL cases.
Results: CD43 was expressed in 100% of patients with CLL, aCLL and MCL and in 33.3% of B-PLL patients. None of the SMZL patients expressed CD43. CLL, aCLL, B-PLL and SMZL groups, all expressed CD200 (100% in cases of CLL, aCLL and SMZL, and 77.8% in cases of B-PLL). On the other hand, none of the MCL expressed CD200. As regards CD1d, it was positively expressed on leukemic cells of 90% of the MCL patients and in all SMZL patients (100%) with a slightly higher mean value observed in SMZL (63.12±17.03) compared to MCL (57.19±24.02), but was not expressed in any patient with CLL, aCLL or B-PLL groups. Concerning CD160, it was positively expressed in all the studied groups, though the incidence of patients positively expressing the marker varied between the groups representing 96.8%, 100%, 40%, 77.8% and 80% in CLL, aCLL, MCL, B-PLL and SMZL respectively.
Conclusion: In conclusion, CD200 is important for the differential diagnosis of CD5+ mature B-cell neoplasms, especially in cases with immunophenotypic aberrancies. Furthermore, CD5+ mature B-cell neoplasms that are CD43- CD200+ should be further discriminated to either SMZL or B-PLL via testing for CD1d expression.